Windlas Biotech Ltd

Windlas Biotech Ltd has announced the closure of its trading window for the company's securities. This closure will be effective from October 1, 2026, and will remain in effect until 48 hours after the unaudited financial results for the quarter and half-year ended September 30, 2026, are made public. This measure is in accordance with the company's internal code of conduct for trading.

Windlas Biotech Ltd announced its unaudited financial results for Q1 FY27, marking the 14th consecutive quarter of record revenue, which stood at ₹248 crores, an 18% year-on-year growth. Adjusted EBITDA grew 26% YoY to ₹34 crores, and Adjusted PAT increased by 37% YoY to ₹25 crores. The company also successfully completed a ₹47 crore share buyback without promoter participation and declared a dividend of ₹13 crores for FY26. The Generic Formulations CDMO vertical was the primary revenue driver, contributing 84% to consolidated revenue with a 29% YoY growth. The Trade Generics & Institutional vertical saw a 32% YoY decline, while the Exports vertical grew by 79% YoY. The company is on track for the commercialization of Plant-6 in H1 FY27.

Windlas Biotech Ltd announced the approval of its Unaudited Standalone Financial Results for the quarter ended June 30, 2026. The Board of Directors met on August 10, 2026, to review and approve these results. The company also submitted the Limited Review Report from its auditors. A significant note indicates that the company is no longer required to prepare consolidated financial statements due to the dissolution of its US subsidiary, Windlas Inc., effective March 31, 2026.

Windlas Biotech Ltd announced that its Board of Directors, in a meeting held on August 10, 2026, approved the Unaudited Standalone Financial Results for the quarter ended June 30, 2026. The company also submitted the Limited Review Report from its auditors. The board meeting commenced at 2:30 PM and concluded at 3:15 PM. The company noted that it is no longer required to prepare consolidated financial statements as its non-operating US subsidiary has been dissolved.

Windlas Biotech Ltd has announced that its Board of Directors will convene on August 10, 2026. The primary agenda item is to consider and approve the un-audited standalone financial results for the first quarter ended June 30, 2026. In line with SEBI regulations, the company's trading window has been closed since July 1, 2026, and will reopen 48 hours after the financial results are declared. This meeting is a routine procedural step for financial reporting.

Windlas Biotech Ltd has announced the record date for its 25th Annual General Meeting (AGM) and e-voting. The cut-off date is set for July 16, 2026, to determine eligible members for voting. The AGM will be held on July 23, 2026, via Video Conferencing (VC)/Other Audio Visual Means (OAVM). Members will have the facility to e-vote from July 20 to July 22, 2026. The agenda includes adopting financial statements, declaring a final dividend of ₹6.30 per equity share, re-appointment of directors Mr. Hitesh Windlass and Mrs. Prachi Jain Windlass, and ratification of the Cost Auditor's remuneration.

Windlas Biotech Ltd has submitted its Annual Report for the financial year ended March 31, 2026, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report, also available on the company's website, includes forward-looking statements regarding anticipated results and prospects. Key investor information such as market capitalization of ₹15,550.01 Millions as of March 31, 2026, CIN, BSE/NSE codes, and a recommended dividend of ₹6.30/- are provided. The 25th Annual General Meeting is scheduled for July 23, 2026, to be held via VC/OAVM. The report details the company's corporate overview, financial performance, research expertise, manufacturing capabilities, future roadmap, business verticals, stakeholder engagement, human resources, and social contributions.

Windlas Biotech Ltd has announced its 25th Annual General Meeting (AGM) will be held on Thursday, July 23, 2026, at 1:00 PM IST via Video Conferencing (VC)/Other Audio Visual Means (OAVM). The meeting will cover ordinary business including the adoption of audited standalone and consolidated financial statements for FY26, declaration of a final dividend of ₹6.30 per equity share, and the re-appointment of directors Mr. Hitesh Windlass and Mrs. Prachi Jain Windlass. Special business includes ratification of the Cost Auditor's remuneration for FY27 and the appointment of Dr. Tarashree Singhal as an Independent Director. E-voting will be available from July 20 to July 22, 2026, with July 16, 2026, set as the cut-off date for determining voting rights.

Windlas Biotech Ltd has issued a notice for its 25th Annual General Meeting (AGM), scheduled for Thursday, July 23, 2026. The meeting will be conducted via Video Conferencing (VC)/Other Audio Visual Means (OAVM) in compliance with MCA and SEBI circulars. Members will have the facility to exercise their voting rights electronically through MUFG Intime India Private Limited's platform. The cut-off date for determining voting eligibility is July 16, 2026. E-voting will be open from July 20 to July 22, 2026.

Windlas Biotech Ltd has announced that its 25th Annual General Meeting (AGM) will be held on July 23, 2026. The company has fixed July 16, 2026, as the record date to determine shareholders eligible for a dividend of ₹6.30 per equity share (126%) for the financial year 2025-26. This dividend recommendation is subject to shareholder approval at the AGM and will be subject to tax deduction at source.